News

The trial is being conducted at UC San Diego Moores Cancer Center. This Phase II G-202 trial will treat up to 34 patients with GBM that has progressed

The claims of the patent (patent number 5479918) cover the use of ADXS-HPV for the treatment of late-stage cervical cancer with a term that extends to 2028. Advaxis

EDGE is the trading and registration platform used by exchanges, brokerage firms and banks in multiple markets throughout the world. Oslo Connect combines the flexibility of the OTC

The deal will create new mobile and internet-based services to support patients through their treatment journey, improving medication adherence and giving patients confidence to manage their condition more

Bioasis is focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier. As part of the deal, MedImmune will assess the therapeutic effect of its

Mogamulizumab, which is branded as ‘POTELIGEO Injection’, is a novel, humanized monoclonal antibody directed against CC chemokine receptor 4 (CCR4), which is over-expressed on various malignant T cells,

Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of degenerative diseases. Magnum’s facilities include a clinic

The move follows an approval from the European Commission in November 2013. Currently, Abilify Maintena is available in several European countries and is progressing through the various Healthcare

Under the deal, BMS will use Five Prime’s platform to move forward its existing immuno-oncology programs by identifying the most viable drug targets for continued research and development.